Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6

Conditions:   Head and Neck Cancer;   Advanced Cancer;   Metastatic Cancer
Intervention:   Drug: Abemaciclib
Sponsor:   Centre Leon Berard
Not yet recruiting

http://ift.tt/2i1MZpi